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Abstract Tryptase-like activities of T and NK cells contribute
to the induction of target cell apoptosis, but only granzyme A
(GzmA) has been shown to exhibit Z-Lys-SBzl esterase activity
in murine T cells. GzmA-deficient mice exhibit residual Z-Lys-
SBzl hydrolyzing activity and almost normal levels of lympho-
cyte-mediated cytotoxicity. Here we report the cloning and
biochemical characterization of recombinant mouse granzyme K
(GzmK). The purified murine protein shows Z-Lys-SBzl hydro-
lyzing activity and is inhibited by bikunin, the light chain of inter-
K-trypsin inhibitor, like the human homolog. We conclude that
GzmK expressed by GzmA-deficient T cells accounts for the
remaining Z-Lys-SBzl activity. Functional similarities between
GzmA and GzmK may explain the subtle immunological deficits
observed in GzmA-deficient mice.
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1. Introduction
Human granzyme K (granzyme 3, tryptase-2) has been pu-
ri¢ed from lymphokine-activated killer cells together with the
granzymes A and B as a third lymphocyte speci¢c granzyme
[1] for which a murine homolog has not been inferred until
recently [2]. Independently, a similar granzyme called RNK-
tryptase-2 with hydrolytic activity for the thiobenzylesters Z-
Lys-SBzl and Z-Arg-SBzl was isolated from the rat natural
killer (NK) cell tumor RNK-16 and cloned at the cDNA level
[3]. Rat granzyme K is identical with fragmentin-3 which was
also characterized as an inducer of DNA fragmentation after
perforin-mediated uptake into target cells [4]. The human ho-
molog for granzyme K has recently been cloned at the cDNA
level and shown to possess hydrolytic activities for the thio-
ester compounds Z-Lys-SBzl and Z-Arg-SBzl [5^7]. In con-
trast, the murine homolog has only been identi¢ed at the
genomic and cDNA level by virtue of its sequence homology
to the rat and human sequences [2].
Granzyme A-de¢cient C57/Bl6 mice were ¢rst reported as
being completely devoid of Z-Lys-SBzl and Z-Arg-SBzl cleav-
ing activity in stimulated T cells and lymphoid organs [8].
Another granzyme A-de¢cient mouse strain obtained by ho-
mologous recombination on a 129/SvJ background, however,
displayed signi¢cant levels of Z-Lys-SBzl cleaving activity in
activated T cell populations [2]. This tryptase-like activity was
detected after prolonged allogeneic stimulation in a mixed
leukocyte reaction, but was not further characterized. In
view of these discrepant data about a second Z-Lys-SBzl
cleaving enzyme in murine T cells, we wished to analyze the
functional properties of puri¢ed murine granzyme K in com-
parison with the recently characterized human granzyme K.
To this end, we have cloned and expressed the murine
granzyme K cDNA in Escherichia coli and processed it to a
functionally active enzyme as described [9]. Here we report
that the murine granzyme K gene indeed encodes a Z-Lys-
SBzl hydrolyzing enzyme which is rapidly inactivated by mur-
ine plasma. Like human granzyme K [9], the murine homolog
interacts with the bikunin component of inter-K-trypsin inhib-
itor. Conservation of the tight binding between granzyme K
and bikunin in men and mice strongly supports the biological
relevance of this interaction.
2. Materials and methods
2.1. Isolation of the gene for mouse granzyme K
An almost full length cDNA probe for rat granzyme K was gen-
erated by PCR on the basis of published sequence data (GenBank
accession number L19694) using the forward and backward primers
DJ100 (5P-ATCTGCTCTGGTTTTCCTTGT-3P) and DJ131 (5P-AA-
ACCACTTGTCATCTCAATGT-3P). This cDNA probe permitted us
to identify the genomic clone C0164 in the murine P1 library
ICRFp703 (strain C57/Bl6) (German resource center, Berlin). A 1.8
kb HindIII subfragment crossreacting with the rat cDNA was sub-
cloned into the vector pUC18 and completely sequenced. This frag-
ment contained exons 1 and 2 and part of intron 2. The exon 1
speci¢c forward primer DJ301 (5P-TTTCTTCATGGGCTCTGGT-
TT-3P) was designed according to this genomic sequence and com-
bined with a backward primer DJ39 (5P-AGGKCYYCCRGA-
RTCHCC-3P) that anneals to the coding region of the highly
conserved peptide GDSGGP containing the active site Ser-195
(chymotrypsin numbering).
2.2. Cloning of the cDNA of mouse GzmK and Northern blotting
PCR ampli¢cation of murine spleen cDNA (Clontech) with DJ301
and DJ39 yielded a 700 bp product that was also sequenced. A mouse
GzmK speci¢c forward primer DJ322 (5P-AAC AAG AAT GTC
CAA CTG CTT-3P) located distal to DJ301 on this sequence was
then designed to obtain the 3P end of murine GzmK by 3P RACE
(rapid ampli¢cation of cDNA ends). The mGzmK speci¢c forward
primer DJ322 and the universal adaptor primer AP2 (5P-ACTCAC-
TATAGGGCTCGAGCGGC-3P) were taken to generate a speci¢c
cDNA fragment from adaptor-ligated mouse spleen cDNA (Clontech)
in a single PCR. The full length sequence of mouse GzmK was then
assembled from these two cDNA segments. Northern blots were per-
formed with total RNA from several cell lines including two Moloney
leukemia virus-transformed T cell lymphomas, two thymoma lines
(BW, L1210) and a CD4-positive (EL-4) and CD8-positive T cell
line CTLL-2. After separation of RNA in formaldehyde agarose
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gels, transfer onto nylon membranes and hybridization with a mouse
cDNA probe, ¢lter membranes were exposed to X-ray ¢lms for
2 days.
2.3. Recombinant expression in E. coli
The cDNA encoding the short N-terminal propeptide Met-Glu and
the mature polypeptide chain of the mouse GzmK gene was ampli¢ed
from mouse spleen cDNA using Pfu-DNA polymerase (Stratagene)
and the gene speci¢c forward and backward primers DJ601 (5P-
TGTGTTTCCATATGGAAATTAT-3P) and DJ515 (5P-AATCTG-
CAGTCTCAATGTGCA-3P), respectively. The resulting 750 bp
PCR product was digested with the restriction enzymes NdeI and
PstI and subcloned into the vector pET24c(+) (Novagen). The
cDNA sequence of this construct was con¢rmed by dideoxy sequenc-
ing and transformed into the E. coli strain B834(DE3) (Novagen) for
protein expression. Inclusion body production, refolding, proteolytic
conversion of mouse GzmK precursors by cathepsin C and puri¢ca-
tion was performed as described [9].
2.4. Activity assays
Hydrolytic activity of GzmK was assayed at room temperature
(RT) in a bu¡er volume of 150 Wl containing 50 mM Tris-HCl, pH
7.6, 150 mM NaCl, 0.01% Triton X-100, 0.3 mM DTNB (Sigma) and
the respective thiobenzylester substrates at concentrations of 0.1 mM.
Z-Lys-SBzl (Z, benzyloxycarbonyl; SBzl, thiobenzylester) (Sigma) was
dissolved in water, Z-Arg-SBzl, Boc-Ala-Ala-Met-SBzl and Boc-Ala-
Ala-Asp-SBzl (all from Enzyme Systems Products, Livermore, USA)
in DMSO. Murine and human GzmK concentrations were determined
by active site titration as described. Hydrolytic activity of 5 nM mouse
GzmK was determined as the rate of hydrolysis by measuring increase
of absorbance at 405 nm wavelength over 5 min using a Dynatech
MR4000 microplate reader.
2.5. Inhibition studies
Various inhibitors (Sigma) were tested against 4 nM mouse GzmK
using 0.3 mM Z-Lys-SBzl as the substrate. Equilibrium dissociation
constants Ki were measured and calculated by non-linear regression
analysis using 6 nM mGzmK, recombinant human bikunin [9] in the
concentration range between 0 and 600 nM, and recombinant bikunin
domain 2 [9] between 0 and 300 nM. Inhibition by plasma proteins
was measured after adding 3 nM mGzmK to 40-fold diluted mouse
plasma in the presence or absence of 0.5 U/ml heparin (Sigma). Re-
sidual enzyme activity was determined after 15 min of preincubation
at RT as described above.
2.6. Molecular modelling of mouse bikunin
The three-dimensional structure of mouse bikunin was modelled
using the known crystal structure of human bikunin as a template
and the program SWISS-MODEL in the ¢rst approach mode acces-
sible via the internet (http://www.expasy.ch/swissmod). The solvent
accessible surface area of mouse bikunin was calculated with the pro-
gram GRASP as described for human bikunin [10].
3. Results and discussion
3.1. Cloning of murine GzmK
Since the murine GzmK cDNA sequence was not known at
the outset of this study and expressed sequence tags of the
murine genome with homology to GzmK were not found in
public databases, we isolated a genomic clone for murine
GzmK from the genomic mouse library ICRFp703 in the
vector pAD10SacBII using an almost full length cDNA probe
of rat GzmK [3]. A 1.8 kb HindIII fragment of the insert was
shown to contain murine GzmK exons by Southern hybrid-
ization. Subsequent sequence analysis of this HindIII frag-
ment clearly con¢rmed the presence of the ¢rst two N-termi-
nal exons by comparisons and sequence alignments with the
rat GzmK cDNA sequence. The missing cDNA of exons 3 to
5 was then established by PCR and 3P RACE from murine
spleen cDNA (Clontech) as described in Section 2. Compar-
isons of the assembled cDNA and derived amino acid sequen-
ces with rat and human GzmK sequences [3,5,7] con¢rmed
that this murine sequence is the closest structural homologue
in the murine genome. No sequence di¡erences were noticed
between this sequence and a recently published genomic se-
quence for the mouse GzmK gene [2].
Expression of murine GzmK has previously been studied in
various mouse tissues including bone marrow, resting spleen
and thymus, but mRNA was only detected at low levels by
RNA protection analyses in interleukin 2-activated lympho-
cytes and in cultured lymphocytes after allogeneic stimulation
for 5 days [2]. We have tested several murine cell lines by
Northern blotting and found moderate expression only in a
CD8-positive T cell line (CTLL-2), but not in T cell lympho-
ma (MBL-2, LSTRA), thymoma (BW, L1210) or CD4-posi-
tive T cell lines (EL-4) (Fig. 1). Thus GzmK appears to be
expressed in a more restricted manner and at lower levels than
the rat and human homologues which are easily detectable in
total RNA of spleen and lung.
Fig. 1. Northern blot analysis of GzmK expression in di¡erent lym-
phoid cell lines. Total RNA from Moloney leukemia virus-trans-
formed lymphoma lines (MBL-2, LSTRA), thymoma lines (BW,
L1210) and CD4-positive (EL-4) and CD8-positive (CTLL-2) T cells
was separated by formaldehyde/agarose gel electrophoresis, blotted
onto a nylon membrane and probed with a radioactively labelled
murine granzyme K cDNA probe. X-ray ¢lms were exposed for
2 days. On the left margin, the position of the 28S and 18S RNA
band is indicated. The GzmK transcript in CTLL-2 cells is marked
by the open arrowhead.
Fig. 2. Hydrolytic speci¢city of recombinant murine GzmK. Enzy-
matic activity of 5 nM mouse GzmK before (short black bars) and
after conversion by cathepsin C (hatched bars) was measured using
four di¡erent thiobenzylester substrates as indicated on the left in ¢-
nal concentrations of 0.1 mM. Increase of absorption per min (in
mOD) at 405 nm was determined over a period of 5 min.
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3.2. Generation and characterization of recombinant mGzmK
Due to the low levels of murine GzmK in immune tissues
and available T cell lines, it is di⁄cult to purify su⁄cient
amounts of mouse GzmK without contaminations by other
enzymes. Previously we showed that the natural proform of
human GzmK can be expressed in E. coli, refolded and con-
verted into an enzymatically active enzyme by bovine cathep-
sin C [9]. The natural propeptide of murine GzmK, however,
is Thr-Glu and was replaced by the human propeptide Met-
Glu to produce the proform of murine GzmK in the cytosol
of E. coli. By this way, murine GzmK was obtained as inclu-
sion bodies in high yields and successfully refolded and con-
verted into a biologically active enzyme after cathepsin C
processing. Fig. 2 shows the enzymatic activity of 5 nM mur-
ine GzmK towards thiobenzylester substrates. Z-Arg-SBzl and
Z-Lys-SBzl were hydrolyzed, but no other substrate. The pro-
form of murine GzmK was catalytically inactive (Fig. 2, black
columns) towards the four thiobenzylester substrates. These
data clearly show that preparations of highly pure murine
GzmK have Z-Lys-S-Bzl activity comparable with that of hu-
man and rat GzmK.
Recently, Z-Lys-S-Bzl activity was studied in GzmA-de¢-
cient alloreactive T cells obtained from two independent
GzmA-de¢cient mouse strains. Hydrolytic activity for Z-
Lys-S-Bzl was not detected in GzmA-de¢cient CTLs from
Table 1
Inhibition of mouse and human GzmK by various inhibitors
Inhibitor Concentration
(mM)
Residual activity (%)
Human
GzmK
Mouse
GzmK
Aprotinin 0.005 6 11
Benzamidine 27.0 45 43
p-Amino-benzamidine 5.0 39 43
Leupeptin 0.2 8 78
Pepstatin A 0.001 104 93
EDTA 0.01 117 106
PefablocSC 1.0 56 6
EGR-CMK 0.1 3 48
FPR-CMK 0.1 2 0
TLCK 0.05 97 81
TPCK 0.05 118 96
Remaining activities of 4 nM mouse GzmK and 3 nM human
GzmK as a percentage of initial activity were determined after
60 min of incubation at room temperature with the respective inhib-
itor. Every value is the average of three independent experiments.
Fig. 3. Inhibition of murine GzmK by human and murine EDTA
plasma in the presence and absence of 0.5 units of heparin/ml. Z-
Lys-SBzl hydrolysis by 5 nM GzmK was measured after 15 min of
incubation by determining the increase of absorption per min at 405
nm. GzmK activity in the absence (black bars) and presence of hep-
arin (hatched bars) is strongly inhibited by 1% human or mouse
plasma.
Fig. 4. Comparative representation of the accessible surface of hu-
man (A) and mouse (B) bikunin using the program GRASP. Blue
indicates positive, red negative and white neutral surface potential.
Primary recognition of tryptase-like target proteases occurs via the
conserved Arg-92 of Kunitz domain 2. The model for mouse biku-
nin (panel B) was constructed with the program SWISS-MODEL in
the ¢rst approach mode using human bikunin as the template.
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C57Bl6 mice [8], low Z-Lys-S-Bzl hydrolyzing activity, how-
ever, in T cell populations from GzmA-de¢cient 129/SvJ mice
[2]. These con£icting data cannot be reconciled by genetic
di¡erences at the GzmK locus, since both strains have an
identical functional GzmK gene as shown in this study. Allor-
eactive GzmA-de¢cient T cells have been shown to express the
message for GzmK [2], but this observation does not proof
that murine GzmK has esterase activity and accounts for
residual Z-Lys-SBzl hydrolyzing activity. Functional studies
with pure recombinant murine GzmK were therefore per-
formed to establish a direct link between GzmK expression
and retained esterase activity in GzmA-de¢cient mice. Low
levels of GzmK in alloreactive T cells and di¡erent T cell
activation protocols are the most likely reasons why Z-Lys-
SBzl esterase activity has not been observed in both GzmA-
de¢cient mouse strains.
3.3. Functional equivalence between mouse and human GzmK
The functional equivalence between murine and human
GzmK was further suggested by inhibition studies demon-
strating that murine GzmK is inhibited by the same inhibitors
as human GzmK including aprotinin of bovine pancreas,
benzamidine and Phe-Pro-Arg-chloromethyl ketone (Table
1). The best inhibitor of human GzmK in plasma, however,
is free bikunin and inter-K-trypsin inhibitor, a covalently
linked protein complex between the light chain bikunin and
one of the three heavy chains H1 to H3 [9]. We, therefore,
tested the inhibition of mGzmK by mouse and human plasma
(Fig. 3). Hundred-fold diluted mouse and human plasma in-
hibited mouse GzmK with high e⁄ciency in the absence of
heparin (Fig. 3). Previous experiments with inhibitors from
human plasma revealed that puri¢ed recombinant bikunin in
fact inhibited human GzmK at concentrations that corre-
spond to the levels of inter-K-trypsin inhibitor in 40-fold di-
luted human plasma [9]. Apparent Ki values were, therefore,
determined for the inhibition of mouse GzmK by human bi-
kunin and the second Kunitz domain of bikunin and
amounted to 33 and 22 nM, respectively. These values are
almost identical with those apparent Ki values that we have
determined for human GzmK (60 nM for bikunin and 27 nM
for bikunin domain 2). Our observations imply that the sur-
faces of human and mouse GzmK that interact with human
bikunin are highly conserved. Likewise the sites for proteinase
interaction in human and murine bikunin should be highly
conserved.
A three-dimensional model for murine bikunin can easily be
constructed from the known crystal structure of human biku-
nin [10] and indicates the conservation of surface features of
the two protease binding loops between positions 88 and 96
(Fig. 4A and B) and positions 111 and 116. The major di¡er-
ences between mouse and human bikunin domains 2 are the
substitutions of Gln-96 and Gln-116 by lysine residues giving
rise to a concentration of positive charges around position 96
in mouse bikunin (Fig. 4B). Conversely, Arg-88 has been re-
placed by a Gln residue in mouse bikunin and thus this sur-
face region appears neutral in mouse bikunin (Fig. 4B). Since
no protease in complex with bikunin has been solved to date,
the conformation of the loop between positions 88 and 96 is
only known for its resting state. By analogy to the complex
formed between trypsin and Kunitz domains 2 of tissue factor
pathway inhibitor (TFPI) [11] it is assumed that the protease
recognition loop undergoes a conformational change and then
binds via Arg-92 and Phe-94 tightly to its cognate enzyme
[10]. Both critical residues are identical in the murine and
human homologues.
Some years ago trypstatin, the second (carboxy-terminal)
Kunitz domain of rat bikunin, has been reported as an e⁄-
cient inhibitor for rat mast cell tryptase [12]. The human
equivalent of trypstatin, however, showed no inhibition of
human mast cell tryptase despite the fact that both critical
residues Arg-92 and Phe-94 are also conserved in rat bikunin
(H. Tschesche, personal communication). Human mast cell
tryptase is known to form a tetrameric complex whose sub-
strate binding regions are arranged around a central hydro-
philic channel [13]. The geometry of this protease complex is
not compatible with inhibition by bikunin or an individual
Kunitz domain. In view of the striking species di¡erences it
appears unlikely that mast cell tryptases are principal targets
of inter-K-trypsin inhibitor.
Binding of proteases to the second Kunitz domain of biku-
nin is also restrained by surface residues of domain 1 which
make close rigid contacts with domain II [10]. This unique
three-dimensional feature of bikunin is probably conserved
in most vertebrate sequences and di¡ers from other proteins
with multiple Kunitz domains which are linked by £exible
peptide spacers. Our ¢nding that mouse GzmK is inhibited
by bikunin as e⁄ciently as human GzmK underscores the
physiological relevance of this interaction and suggests that
recognition sites for both inhibitors and substrates are con-
served in human and rodent homologues of GzmK.
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